Clinical Trial Update: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy, safety, and tolerability of remibrutinib in adults and adolescents with moderate to severe hidradenitis suppurativa is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING